StockNews.com assumed coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a report issued on Tuesday morning. The brokerage issued a hold rating on the stock.
NantHealth Stock Performance
NASDAQ:NH opened at $2.26 on Tuesday. NantHealth has a one year low of $1.57 and a one year high of $11.98. The stock has a market cap of $17.42 million, a PE ratio of -0.30 and a beta of 1.86. The stock has a 50 day moving average price of $2.98 and a 200 day moving average price of $1.72.
Get NantHealth alerts:Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of NH. Atria Wealth Solutions Inc. boosted its position in shares of NantHealth by 117.7% during the second quarter. Atria Wealth Solutions Inc. now owns 491,942 shares of the company's stock worth $205,000 after buying an additional 265,949 shares during the period. Millennium Management LLC purchased a new position in shares of NantHealth during the second quarter worth $110,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of NantHealth during the second quarter worth $36,000. 4.50% of the stock is currently owned by hedge funds and other institutional investors.
NantHealth Company Profile
(Get Rating)
NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.
Featured Stories
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
- 10 Best Consumer Discretionary ETFs
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.